HRP20171620T1 - N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol - Google Patents

N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol Download PDF

Info

Publication number
HRP20171620T1
HRP20171620T1 HRP20171620TT HRP20171620T HRP20171620T1 HR P20171620 T1 HRP20171620 T1 HR P20171620T1 HR P20171620T T HRP20171620T T HR P20171620TT HR P20171620 T HRP20171620 T HR P20171620T HR P20171620 T1 HRP20171620 T1 HR P20171620T1
Authority
HR
Croatia
Prior art keywords
compound
salt
hemisulfate salt
degrees
specified
Prior art date
Application number
HRP20171620TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171620(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20171620T1 publication Critical patent/HRP20171620T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20171620TT 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol HRP20171620T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
EP13708603.9A EP2820016B1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number Publication Date
HRP20171620T1 true HRP20171620T1 (hr) 2017-12-01

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171620TT HRP20171620T1 (hr) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol
HRP20191655 HRP20191655T1 (hr) 2012-02-27 2019-09-16 N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191655 HRP20191655T1 (hr) 2012-02-27 2019-09-16 N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol

Country Status (26)

Country Link
US (1) US8759372B2 (enExample)
EP (2) EP3254681B1 (enExample)
JP (2) JP6208154B2 (enExample)
KR (2) KR102076118B1 (enExample)
CN (1) CN104136437B (enExample)
AU (1) AU2013226361B2 (enExample)
BR (1) BR112014021032B1 (enExample)
CA (1) CA2865585C (enExample)
CY (2) CY1119448T1 (enExample)
DK (2) DK2820016T3 (enExample)
EA (1) EA025358B1 (enExample)
ES (2) ES2746031T3 (enExample)
HK (1) HK1248111B (enExample)
HR (2) HRP20171620T1 (enExample)
HU (2) HUE034936T2 (enExample)
IL (1) IL234272B (enExample)
LT (2) LT2820016T (enExample)
MX (1) MX352171B (enExample)
NO (1) NO2935439T3 (enExample)
PL (2) PL2820016T3 (enExample)
PT (2) PT3254681T (enExample)
RS (2) RS56556B1 (enExample)
SG (1) SG11201404834XA (enExample)
SI (2) SI2820016T1 (enExample)
SM (1) SMT201700489T1 (enExample)
WO (1) WO2013130402A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211929B2 (en) 2012-01-26 2016-05-26 Christopher J. Soares Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
US20220249471A1 (en) * 2019-06-14 2022-08-11 The Regents Of The University Of California New therapeutic approach to lung disease
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2558274A1 (en) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
DE602005027230D1 (de) 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
EP2007763A2 (en) 2006-04-10 2008-12-31 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato

Also Published As

Publication number Publication date
HUE047050T2 (hu) 2020-04-28
HUE034936T2 (hu) 2018-03-28
PT3254681T (pt) 2019-10-01
KR102076118B1 (ko) 2020-02-11
LT2820016T (lt) 2017-10-25
ES2642737T3 (es) 2017-11-17
BR112014021032B1 (pt) 2022-09-27
KR102220969B1 (ko) 2021-02-25
IL234272B (en) 2018-10-31
JP2015511581A (ja) 2015-04-20
EP2820016B1 (en) 2017-08-02
PT2820016T (pt) 2017-10-18
DK3254681T3 (da) 2019-09-30
CN104136437B (zh) 2016-05-11
HK1248111B (en) 2020-04-17
CY1119448T1 (el) 2018-03-07
EA025358B1 (ru) 2016-12-30
RS56556B1 (sr) 2018-02-28
LT3254681T (lt) 2019-09-25
DK2820016T3 (da) 2017-11-13
EP3254681B1 (en) 2019-06-19
NO2935439T3 (enExample) 2018-03-31
AU2013226361B2 (en) 2017-09-21
EA201491585A1 (ru) 2015-01-30
SMT201700489T1 (it) 2017-11-15
SI2820016T1 (sl) 2017-11-30
CA2865585C (en) 2019-12-10
EP3254681A1 (en) 2017-12-13
KR20140130140A (ko) 2014-11-07
CA2865585A1 (en) 2013-09-06
CY1122121T1 (el) 2020-11-25
JP2017226693A (ja) 2017-12-28
JP6476253B2 (ja) 2019-02-27
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
AU2013226361A1 (en) 2014-10-16
CN104136437A (zh) 2014-11-05
BR112014021032A2 (enExample) 2017-06-20
MX352171B (es) 2017-11-13
US20130225636A1 (en) 2013-08-29
JP6208154B2 (ja) 2017-10-04
EP2820016A1 (en) 2015-01-07
WO2013130402A1 (en) 2013-09-06
ES2746031T3 (es) 2020-03-04
SG11201404834XA (en) 2014-09-26
KR20200016993A (ko) 2020-02-17
SI3254681T1 (sl) 2019-10-30
HRP20191655T1 (hr) 2019-12-13
US8759372B2 (en) 2014-06-24
PL3254681T3 (pl) 2019-12-31
RS59295B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
HRP20171620T1 (hr) N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol
AU2023203088B2 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
JP2014518286A5 (enExample)
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
AR108672A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso
HK1210771A1 (zh) 氮杂吲哚衍生物
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
TN2012000139A1 (en) Cgrp receptor antagonists
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
AR081315A1 (es) Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
MX336224B (es) Quinolinas sustituidas y su uso como medicamentos.
HRP20161742T4 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
HRP20140814T1 (hr) Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma
ME02019B (me) SPOJ IMIDAZ0[4,5-c]KINOLIN-2-0NA I NJEGOVA UPOTREBA KAO DVOJNOG INHIBITORA PI3 KINAZE I MTOR"
AR091781A1 (es) Antagonistas del receptor de 5-ht3
JP2016507502A5 (enExample)
RU2018135967A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
AU2023328411A1 (en) Novel nlrp3 inflammasome inhibitors
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
JP2010530427A (ja) 多環式グアニン誘導体およびその使用方法
EA201690515A1 (ru) Производные диазокарбазола в качестве пэт-лигандов белка tau
HRP20160495T1 (hr) Morfolinilbenzotriazini za uporabu u terapiji raka
JP2016508135A5 (enExample)
BRPI0816219B8 (pt) compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk